1. Introduction {#s0005}
===============

Sickle cell anaemia (SCA) is caused by a mutation in the β globin gene. Sickle haemoglobin (HbS) polymerises when deoxygenated, resulting in red cell membrane rigidity and surface protein modifications that subsequently contribute to vaso-occlusion. SCA is seldom symptomatic in the first six months of life. One main explanation lies in the sustained level of foetal haemoglobin (HbF) and F cells during this period ([@bb0005]) preventing HbS polymerisation ([@bb0010]). However, infra clinical vaso occlusion, particularly in the spleen, occurs at a very early age ([@bb0015]) and the absolute reticulocyte count is already elevated in the first semester of life, arguing for the very early onset of haemolysis despite high HbF levels ([@bb0020], [@bb0025]). Furthermore, increased evidence supports that HbF elevation during hydroxycarbamide therapy is insufficient to explain the drug\'s beneficial effect ([@bb0030]). In fact, it is now considered that abnormal red blood cell (RBC) adhesiveness in SCA through activation, sustained or increased expression of adhesion molecules is pivotal in the genesis of vaso occlusive crisis, the hallmark of SCA ([@bb0035]). In this study, we analysed the expression pattern of 9 adhesion molecules on both reticulocytes and mature RBCs in SCA and non-SCA very young infants. These markers are known surface molecules, which allow characterisation of erythroid maturation and/or which are adhesion molecules demonstrated to play an important pathophysiological role ([@bb0040]). Our objectives were to gain insight into very early pathophysiology by evidencing distinct profiles specifically attributable to SCA.

2. Material and Methods {#s0010}
=======================

2.1. Patients {#s0025}
-------------

Infants diagnosed with SS or S beta° genotypes following neonatal screening were enrolled in a multi-centre prospective study on prognostic factors in SCA (ClinicalTrials.gov: [NCT01207037](ctgov:NCT01207037){#ir0010}) between September 2010 and March 2013. The institutional review boards of all participating centres approved the study. Written informed consent in accordance with the Declaration of Helsinki was obtained from all parents. Blood sampling was performed at enrolment (3--6 months) at steady state, in asymptomatic infants. In parallel, blood samples from infants with no haemoglobinopathy (non-SCA-infants) were collected.

For each patient complete blood counts, erythrocyte indices were determined using an Advia 120 Hematology System (SIEMENS, Germany).

HbF was quantified by high performance ion-exchange liquid chromatography (HPLC) procedure (BioRad Laboratories, California, USA).

Samples were stored at − 196 °C as previously described ([@bb0040]) at the Centre National de Référence pour les Groupes Sanguins, Paris, for secondary flow cytometry analysis.

2.2. Flow Cytometry {#s0030}
-------------------

Flow cytometry analysis was performed using murine monoclonal antibodies against the adhesion molecules CD36, CD44, CD47, CD49d, CD58, CD99, CD147, CD239 and CD242. A BD FACScanto II flow cytometer with HTS (Becton-Dickinson) and FACSDiva software (v6.1.3) were used for acquisition and analysis. The percentage of RBCs expressing each marker and the corresponding mean fluorescence intensity (MFI) were determined under the same conditions for all samples. The percentage of reticulocytes was determined using thiazole orange dye (Retic-CountTM, Becton-Dickinson, San Jose, CA, USA) according to the manufacturer instructions. A total of 10,000 events was analysed for each patient and each molecule.

2.3. Statistical Analysis {#s0035}
-------------------------

Results are presented as means or medians ± SD. Statistical analysis was performed with GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) using Mann--Whitney test. A difference between two groups was considered statistically significant when *P* \< 0.05.

3. Results {#s0015}
==========

3.1. Asymptomatic SCA Infants Show Early Haemolytic Anaemia Despite Sustained HbF Level ([Table 1](#t0005){ref-type="table"}) {#s0040}
-----------------------------------------------------------------------------------------------------------------------------

Fifty-four SCA infants were analysed and compared to 17 non-SCA infants. Median age in the two groups was not statistically different (144 days, range 81--196 versus 128, range 68--621, *P* = 0.84) so that no difference in subsequent results would be attributable to this age parameter. Of note and as expected, none of the SCA infants had clinical symptoms related to the disease.

Mean HbF level in SCA infants was 41.2% (± 11.2), a value 2--4 fold higher than reference values (10.4% ± 1.8) ([@bb0005], [@bb0045]), and statistically increased when compared to non-SCA infants (5.7% ± 3.6, *P* \< 0.0001).

Median Hb level in SCA infants was 9.1 g/dL (6.5--12), a value significantly decreased in comparison with non-SCA infants (11 g/dL, 7.2--12.6, *P* \< 0.001) whilst median reticulocyte percentage was increased in SCA infants (2.9%, 0.5--10 vs 2%, 0.5--4.2, *P* = 0.04).

3.2. Flow Cytometry Analysis of SCA Reticulocytes Demonstrates Increased Expression of Erythroid Adhesion Markers {#s0045}
-----------------------------------------------------------------------------------------------------------------

Reticulocytes from SCA infants displayed an overall statistically increased expression of the following surface markers: CD239 (Lu/BCAM), CD242 (ICAM-4/LW), CD58 (LFA-3), CD47 (IAP), CD99 (MIC2), CD147 (Basigin) and CD44 ([Fig. 1](#f0005){ref-type="fig"}). Because we calculated a ratio of positive reticulocytes on total reticulocytes, these findings are not related to the globally increased percentage of reticulocytes in SCA infants. Conversely, no significant differences were found on mature RBCs between SCA and non-SCA patients (data not shown).

3.3. Lu/BCAM, ICAM-4 and LFA-3 are Overexpressed on SCA Reticulocytes {#s0050}
---------------------------------------------------------------------

To further characterise the reticulocyte population in terms of surface molecule expression, we analysed the protein expression level of the 9 surface markers by measuring their mean fluorescence intensity (MFI). Here, MFI was statistically increased concerning two erythroid adhesion molecules involved in SCA pathophysiology, namely Lu/BCAM and ICAM-4, and a poorly described molecule in RBC physiology: LFA-3 ([Fig. 2](#f0010){ref-type="fig"}).

4. Discussion {#s0020}
=============

Translational research is limited in SCA very young infants either because diagnosis is delayed or because, in case of neonatal diagnosis, parental approval for clinical trials is extremely difficult to obtain at a very young age in the setting of such a severe disease. Here, we confirm in a larger cohort of SCA infants aged less than 6 months, the very early onset of haemolytic anaemia contrasting with the slow decline of HbF. These results, consistent with previous reports ([@bb0005], [@bb0050]), illustrate the pitfall of considering elevated HbF level as protective. Measuring global HbF level by HPLC or enumerating F cells overlooks the content of HbF at a cellular level because the number of F-cells with polymer-inhibiting concentrations of HbF is a more important determinant than the concentration of HbF in the hemolysate or the total number of F-cells. However, quantitative methods for measuring the amount of HbF in each F-cell (HbF/F-cell) and plotting the distribution of HbF among F-cells are not available ([@bb0050]). Measuring HbF does not address therefore the heterogeneous distribution of HbF within RBCs and hence subpopulations of RBCs prone to polymerisation, sickling and haemolysis because of their very low content in HbF. These numerically small subpopulations may in fact play an important pathophysiological role.

Erythroid adhesion molecules play a role in normal red blood cell (RBC) physiology during erythropoiesis and erythrophagocytosis. Expression level, clustering and activation state are critical for the adhesive function. In normal conditions, circulating RBCs are not supposed to adhere to any other cells nor to extracellular matrix components. Most molecules therefore display a decreasing level of expression throughout erythropoiesis. Our data demonstrates that between 3 and 5 months of age, reticulocytes characterised by markers that are otherwise lost or decreased upon maturation, are found in the circulation. At this same time point, mature RBCs display no significant differences compared to non-SCA, consistent with our hypothesis that their release occurred shortly after birth at a time when no dyserythropoiesis is expected to occur, as the HbF switch has not begun. This time frame, therefore, allows a snapshot of the first pathological changes occurring in SCA: the release of reticulocytes with a distinctive profile of stress reticulocytes.

Cytometric analysis of SCA RBCs indeed evidenced reticulocytes overexpressing the erythroid adhesion molecules: Lu/BCAM, ICAM-4 and LFA-3, whilst no difference was evidenced on mature red cells. Overexpression of Lu/BCAM and ICAM-4 has been demonstrated in SCA ([@bb0055], [@bb0060]) and, importantly, functional activation by phosphorylation ([@bb0065]) results in increased RBC adhesion to vascular endothelium and resistance to high shear-stress forces, thereby contributing to VOC genesis ([@bb0070]). Lu/BCAM is the carrier of the Lutheran and the BCAM antigens and the unique erythroid receptor for laminin α5 chain, a major component of the sub endothelial extracellular matrix. It is expressed both on erythroid and endothelial cells and is a receptor for α4β1 integrin expressed on sickle reticulocytes and leukocytes ([@bb0075], [@bb0080]).

ICAM-4 carries the antigens of the Landsteiner--Wiener (LW) blood group system and is a ligand for a large repertoire of integrins including αVβ3 present on endothelial cells. ICAM-4 undergoes phosphorylation on serine along the PKA-dependent pathway. In addition to its adhesive interaction with endothelial cells, ICAM-4 was shown to play a critical role in vaso-occlusion in murine models through its interaction with αVβ3 ([@bb0085]). Conversely, no data is available on the role of LFA-3 in erythroid cells, but growing evidence points to LFA-3 as a novel functional marker involved in regulating the self-renewal of tumour-initiating cells in colorectal cancer ([@bb0090]). Interestingly, LFA-3 was found on the surface of exosomes released by rat reticulocytes pointing out a mechanism through which it is down regulated during terminal erythroid maturation ([@bb0095]).

Known adhesion markers previously identified on SCA reticulocytes i.e., CD36 and CD49d (α4β1/Very Late Antigen-4) ([@bb0100], [@bb0105]) were not significantly increased in our SCA infant cohort ([Fig. 1](#f0005){ref-type="fig"}). This discrepancy may be explained by the overall relatively low percentage of reticulocytes, as opposed to adults, and is consistent with the findings of Odièvre et al. in SCA children ([@bb0110]).

Recent publications have pointed to the significance of an elevated reticulocyte count in association with disease severity ([@bb0020], [@bb0025]). In this study we confirm the very early onset of reticulocytosis in SCA infants and demonstrate the presence of circulating stress reticulocytes with a specific adhesion molecule profile, overexpressing the adhesion molecules Lu/BCAM, ICAM-4 and LFA-3. This numerically small subpopulation of reticulocytes expressing Lu/BCAM, ICAM-4 and LFA-3 could play a role in early infancy notably in splenic injury as these cells would be prone to splenic trapping in the open circulation of the filtering beds, through adhesion to laminin and/or the spleen-specific endothelial cells of the venous sinus ([@bb0115]). Ongoing longitudinal analysis will confirm if this idiosyncratic erythroid adhesion molecule profile in infants indeed correlates with increased haemolysis and adhesion, functional activation and disease severity.
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###### 

Patient characteristics.

                                      SCA             Control          *P*
  ----------------------------------- --------------- ---------------- -----------
  Age, days (median, range)           144 (81--196)   128 (68--621)    0.84
  Haemoglobin, g/dL (median, range)   9.1 (6.5--12)   11 (7.2--12.6)   \< 0.0001
  Reticulocytes, % (median, range)    2.9 (0.5--10)   2 (0.5--4.2)     0.04
